(Q42499967)

1 November 2017

title

Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model (English)

1 reference

1 November 2017

1 reference

Alba Minelli

1

1 reference

1 November 2017

C Conte

2

1 reference

1 November 2017

I Cacciatore

3

1 reference

1 November 2017

C Cornacchia

4

1 reference

1 November 2017

F Pinnen

5

1 reference

1 November 2017

publication date

5 January 2012

1 reference

1 November 2017

1 reference

1 November 2017

volume

43

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

1359-1367

1 reference

Gly-Pro-Glu protects beta-amyloid-induced somatostatin depletion in the rat cortex.

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Kinetics of nigral degeneration in a chronic model of MPTP-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Synthesis and pharmacological evaluation of side chain modified glutamic acid analogues of the neuroprotective agent glycyl-L-prolyl-L-glutamic acid (GPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

L-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Toxic effects of dopamine metabolism in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Interaction among heme oxygenase, nuclear factor-kappaB, and transcription activating factors in cardiac hypertrophy in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Melatonin ameliorates cerulein-induced pancreatitis by the modulation of nuclear erythroid 2-related factor 2 and nuclear factor-kappaB in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Cyclo(His-Pro) up-regulates heme oxygenase 1 via activation of Nrf2-ARE signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

L-dopa therapy for Parkinson's disease: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Synthesis and study of L-dopa-glutathione codrugs as new anti-Parkinson agents with free radical scavenging properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Etiology and pathogenesis of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Neurochemical findings in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Delayed peripheral administration of the N-terminal tripeptide of IGF-1 (GPE) reduces brain damage following microsphere induced embolic damage in young adult and aged rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Levodopa--toxic or neuroprotective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-011-1210-X

10.1007/S00726-011-1210-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 November 2017

1023725419

0 references

1 reference